Press Releases

Indegene and TranScrip launch IntraScience - an innovative regulatory, safety and medical services solution for global bio-pharmaceutical companies

IntraScience logo.pngMay 25, 2016 Iselin, NJ, USA and Reading, UK: Indegene (www.indegene.com), a leading global provider of clinical, commercial, and marketing solutions to life science, pharmaceutical, and healthcare organisations and TranScrip (www.transcrip-partners.com), a renowned global provider of innovative scientific support throughout the product lifecycle, today announced the extension of their existing alliance with the launch of IntraScience.

IntraScience covers the full spectrum of business process solutions to clinical, regulatory, safety and medical affairs from early drug development to mature products. It uniquely combines a full range of global operational activities provided by large operational, pharmacovigilance and medical affairs CROs with a solid base of highly experienced big pharma- and biotech-trained therapeutic and functional staff from Europe and the US.

For large pharma clients, IntraScience seamlessly integrates Indegene and TranScrip staff with client teams for highly cost-effective, top quality deliverables. For smaller clients, IntraScience offers comprehensive managed services, such as end-to-end pharmacovigilance/drug safety, throughout product development and lifecycle. For both large and small clients, the service will reduce risk and create value through innovation coming from experienced teams of scientists, physicians, software developers, business development experts and project managers. The flexibility of the IntraScience team allows a responsive customer relationship adding value whether the client is a small biotech with an early development pipeline and no registered products or is one of the top 20 pharma companies with an extensive portfolio of marketed products.

Mr. Manish Gupta, CEO, Indegene, said: "Indegene is excited to set up IntraScience with TranScrip, a uniquely experienced biopharma support organisation. Through this partnership, our highly experienced drug development and medical affairs teams will provide global delivery of end-to-end pharmacovigilance and regulatory services including medical monitoring and call centres across five continents.”

Dr Flic Gabbay, Managing Partner, TranScrip said: “The IntraScience model, where offshoring and nearshoring are combined, will resolve many of the resourcing challenges within big pharma and biotech and bring a more personal touch to this kind of service. We are thrilled to have Indegene as our partner. Our combined value proposition will help address several of the unmet needs of the industry.”

------------------------------------------------------------------------------------------------------------------------------------

About Indegene

Indegene is a leading provider of clinical, commercial, and marketing solutions to global pharmaceutical and healthcare organisations. By seamlessly integrating analytics, technology, operations and medical expertise (ATOM), Indegene partners with clients to increase both productivity and revenues by delivering better patient outcomes, optimising cost, enhancing R&D agility and improving sales and marketing effectiveness. Indegene applies deep scientific knowledge, flexible delivery models, proprietary technology, and a client-centric approach to drive transformational initiatives in drug safety, regulatory and medical affairs, e-learning and development, data analytics, multi-channel customer engagement.

With offices in the United States, Canada, United Kingdom, China, India, and Australia, Indegene partners globally with clients; leverages a global talent pool of clinicians, technologists, creative specialists, domain experts, and business process specialists; deploys global infrastructure assets; and harnesses global healthcare knowledge to solve client challenges.

About TranScrip

TranScrip supports the development and lifecycle management of biopharmaceutical products. TranScrip provides expertise, resourcing and strategic oversight from translational medicine to successful registration and market access. With more than 100 clients including many top 20 pharmas in its portfolio, TranScrip’s insightful virtual teams have delivered one or two MAAs and NDAs every year alongside a range of many other services covering drug safety, translational medicine, clinical development, medical affairs and commercial projects.

TranScrip has offices in the United States, United Kingdom, Ghana, Hong Kong and Australia. TranScrip teams offer a depth of expertise in different therapeutic areas including oncology, respiratory, infectious diseases, internal medicine, inflammation and CNS/pain.